Author's posts
Would Routine Genomic Testing For Cancer And Heart Risk Make Economic Sense?
One Yale genetics expert argues that population-wide genomic screening would be worth it, even if only 1% of Americans were to learn they have genetic abnormalities that put them at high risk for deadly diseases.
When Sharks Attack Lung Disease — And More Science You Won’t Learn On ‘Shark Week’
While the Discovery Channel frightens viewers during the 30th year of Shark Week, scientists are embracing the creatures for their potential to inspire life-saving therapies.
FDA To Consider Drug Importation In Battle Against High Drug Prices
FDA Commissioner Scott Gottlieb, once a critic of drug importation, is now tasked with the challenge of figuring out whether bringing certain low-cost drugs in from overseas will provide price relief for consumers.
This Startup Is Developing Finger-Prick Blood Tests, But Don’t Call It Theranos 2
Sight Diagnostics believes it can succeed where Theranos failed, developing rapid finger-prick blood tests, but it’s approach is nothing like that of the failed Silicon Valley startup chronicled in the bestselling book Bad Blood.
Healthcare VC Investing Could Hit A Record High In 2018
In the second quarter alone, $5.3 billion in venture capital was invested in 216 healthcare deals, placing the sector at number two on the list of the top five fundraisers. And all signs are pointing to continued investor enthusiasm for the sector.
As Biotech IPOs Boom Again, Here Are 5 To Watch
Last week, eight biotech companies went public on Nasdaq, raising a total of $645 million and adding $3.3 billion in market valuation to the sector. This has been another active week, and there are even more biotech IPOs to come.
Immigrants And U.S. Healthcare: What One Med School Dean Wants Congress To Know
From H1B visa holders to dreamers, immigrants working in medicine and science are making a vital contribution to the U.S. healthcare, says one medical school dean who will be watching today’s vote carefully.
Biotech Executives Fret Over Hassles And Uncertainties Of ‘Right To Try’
Drug makers that agree to provide access to experimental treatments under the Right to Try act may be putting the future approval of their treatments at risk, some CEOs argue.
- 1
- 2
